Report Detail
Global Subcutaneous Injectable Suspensions Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application
- RnM4365285 |
- 08 January, 2022 |
- Global |
- 100 Pages |
- QYResearch |
- Medical Industry
Summary:
Market Insights
The research report studies the Subcutaneous Injectable Suspensions market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
Due to the COVID-19 pandemic, the global Subcutaneous Injectable Suspensions market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.
The global main companies of Subcutaneous Injectable Suspensions include Merck Sharp & Dohme, Novo Nordisk, Lilly, Biocon Limited, Pfizer, BeiGene, EnteraBio, AbbVie and Pfizer Limited, etc. In 2021, the global six largest players have a share approximately % in terms of revenue.
The North America Subcutaneous Injectable Suspensions market is estimated at US$ million in 2021, while China is forecast to reach US$ million by 2028. The proportion of the China is % in 2021 and it is predicted that the share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Subcutaneous Injectable Suspensions landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Single-Dose Injections accounting for % of the Subcutaneous Injectable Suspensions global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
Segment Scope
An intensive study of key type and application segments has been done in this segmentation section. The authors of the report have provided reliable figures including revenue forecast data by type and application for the period 2017-2028. They have also studied how the segments are gaining or losing growth in various geographies and their respective countries. Thanks to this study, readers can thoroughly grasp the growth pattern and potential of different segments.
Segment by Type
Single-Dose Injections
Multiple-Dose Injections
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Scope
This segment of the report offers a thorough regional study of the global Subcutaneous Injectable Suspensions market. Drivers and restraints for each region are broadly examined in the report. Readers will get familiar with the driving forces and challenges that are specific to the regions. The specialists have identified growth opportunities in key geographical regions and their respective countries to aid players to reinforce their presence. All the regions and their countries in the report are assessed based on the growth rate and revenue according to the consumption for the period 2017-2028. This geographical analysis will help readers to gain in-depth knowledge of the regional growth. The key geographical regions surveyed in this research report involve North America, Europe, Asia Pacific, Central and South America, and Middle East and Africa. The report has specifically covered major countries including United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
Key Players
This section has provided an exhaustive analysis of the strategies that the companies are focusing on to stay ahead of other players. The strategies mainly involve research and development, new product developments, and mergers and acquisitions. The researchers have also provided revenue shares of the key companies, company overview, and the latest company developments so as to help players to sustain the cutthroat competition. In this section, the report offers global revenue data of manufacturers for the period 2017-2022. Following is the list of key manufacturers observed in this research study:
Merck Sharp & Dohme
Novo Nordisk
Lilly
Biocon Limited
Pfizer
BeiGene
EnteraBio
AbbVie
Pfizer Limited
Teva Pharmaceuticals USA
Bristol-Myers Squibb
Cipla
Baxter International
AstraZeneca
Frequently Asked Questions
Which application segment captured the leading share in the Subcutaneous Injectable Suspensions market?
How fragmented is the Subcutaneous Injectable Suspensions market?
Which are the key growth drivers in the Subcutaneous Injectable Suspensions market?
Which are the top strategies undertaken by the Subcutaneous Injectable Suspensions market players?
Which technological trends are likely to affect the Subcutaneous Injectable Suspensions market?
What is the expected Subcutaneous Injectable Suspensions market size by 2028?
Which companies are dominating the Subcutaneous Injectable Suspensions market?
Which region is projected to witness the fastest growth in the future?
What factors are restraining the Subcutaneous Injectable Suspensions market growth?
Which are the emerging companies in the Subcutaneous Injectable Suspensions market?
Table of Contents
1 Market Overview of Subcutaneous Injectable Suspensions
- 1.1 Subcutaneous Injectable Suspensions Market Overview
- 1.1.1 Subcutaneous Injectable Suspensions Product Scope
- 1.1.2 Subcutaneous Injectable Suspensions Market Status and Outlook
- 1.2 Global Subcutaneous Injectable Suspensions Market Size Overview by Region 2017 VS 2021 VS 2028
- 1.3 Global Subcutaneous Injectable Suspensions Market Size by Region (2017-2028)
- 1.4 Global Subcutaneous Injectable Suspensions Historic Market Size by Region (2017-2022)
- 1.5 Global Subcutaneous Injectable Suspensions Market Size Forecast by Region (2023-2028)
- 1.6 Key Regions, Subcutaneous Injectable Suspensions Market Size (2017-2028)
- 1.6.1 North America Subcutaneous Injectable Suspensions Market Size (2017-2028)
- 1.6.2 Europe Subcutaneous Injectable Suspensions Market Size (2017-2028)
- 1.6.3 Asia-Pacific Subcutaneous Injectable Suspensions Market Size (2017-2028)
- 1.6.4 Latin America Subcutaneous Injectable Suspensions Market Size (2017-2028)
- 1.6.5 Middle East & Africa Subcutaneous Injectable Suspensions Market Size (2017-2028)
2 Subcutaneous Injectable Suspensions Market Overview by Type
- 2.1 Global Subcutaneous Injectable Suspensions Market Size by Type: 2017 VS 2021 VS 2028
- 2.2 Global Subcutaneous Injectable Suspensions Historic Market Size by Type (2017-2022)
- 2.3 Global Subcutaneous Injectable Suspensions Forecasted Market Size by Type (2023-2028)
- 2.4 Single-Dose Injections
- 2.5 Multiple-Dose Injections
3 Subcutaneous Injectable Suspensions Market Overview by Application
- 3.1 Global Subcutaneous Injectable Suspensions Market Size by Application: 2017 VS 2021 VS 2028
- 3.2 Global Subcutaneous Injectable Suspensions Historic Market Size by Application (2017-2022)
- 3.3 Global Subcutaneous Injectable Suspensions Forecasted Market Size by Application (2023-2028)
- 3.4 Hospitals Pharmacies
- 3.5 Retail Pharmacies
- 3.6 Online Pharmacies
4 Subcutaneous Injectable Suspensions Competition Analysis by Players
- 4.1 Global Subcutaneous Injectable Suspensions Market Size by Players (2017-2022)
- 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Subcutaneous Injectable Suspensions as of 2021)
- 4.3 Date of Key Players Enter into Subcutaneous Injectable Suspensions Market
- 4.4 Global Top Players Subcutaneous Injectable Suspensions Headquarters and Area Served
- 4.5 Key Players Subcutaneous Injectable Suspensions Product Solution and Service
- 4.6 Competitive Status
- 4.6.1 Subcutaneous Injectable Suspensions Market Concentration Rate
- 4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
- 5.1 Merck Sharp & Dohme
- 5.1.1 Merck Sharp & Dohme Profile
- 5.1.2 Merck Sharp & Dohme Main Business
- 5.1.3 Merck Sharp & Dohme Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.1.4 Merck Sharp & Dohme Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.1.5 Merck Sharp & Dohme Recent Developments
- 5.2 Novo Nordisk
- 5.2.1 Novo Nordisk Profile
- 5.2.2 Novo Nordisk Main Business
- 5.2.3 Novo Nordisk Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.2.4 Novo Nordisk Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.2.5 Novo Nordisk Recent Developments
- 5.3 Lilly
- 5.3.1 Lilly Profile
- 5.3.2 Lilly Main Business
- 5.3.3 Lilly Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.3.4 Lilly Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.3.5 Biocon Limited Recent Developments
- 5.4 Biocon Limited
- 5.4.1 Biocon Limited Profile
- 5.4.2 Biocon Limited Main Business
- 5.4.3 Biocon Limited Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.4.4 Biocon Limited Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.4.5 Biocon Limited Recent Developments
- 5.5 Pfizer
- 5.5.1 Pfizer Profile
- 5.5.2 Pfizer Main Business
- 5.5.3 Pfizer Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.5.4 Pfizer Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.5.5 Pfizer Recent Developments
- 5.6 BeiGene
- 5.6.1 BeiGene Profile
- 5.6.2 BeiGene Main Business
- 5.6.3 BeiGene Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.6.4 BeiGene Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.6.5 BeiGene Recent Developments
- 5.7 EnteraBio
- 5.7.1 EnteraBio Profile
- 5.7.2 EnteraBio Main Business
- 5.7.3 EnteraBio Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.7.4 EnteraBio Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.7.5 EnteraBio Recent Developments
- 5.8 AbbVie
- 5.8.1 AbbVie Profile
- 5.8.2 AbbVie Main Business
- 5.8.3 AbbVie Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.8.4 AbbVie Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.8.5 AbbVie Recent Developments
- 5.9 Pfizer Limited
- 5.9.1 Pfizer Limited Profile
- 5.9.2 Pfizer Limited Main Business
- 5.9.3 Pfizer Limited Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.9.4 Pfizer Limited Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.9.5 Pfizer Limited Recent Developments
- 5.10 Teva Pharmaceuticals USA
- 5.10.1 Teva Pharmaceuticals USA Profile
- 5.10.2 Teva Pharmaceuticals USA Main Business
- 5.10.3 Teva Pharmaceuticals USA Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.10.4 Teva Pharmaceuticals USA Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.10.5 Teva Pharmaceuticals USA Recent Developments
- 5.11 Bristol-Myers Squibb
- 5.11.1 Bristol-Myers Squibb Profile
- 5.11.2 Bristol-Myers Squibb Main Business
- 5.11.3 Bristol-Myers Squibb Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.11.4 Bristol-Myers Squibb Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.11.5 Bristol-Myers Squibb Recent Developments
- 5.12 Cipla
- 5.12.1 Cipla Profile
- 5.12.2 Cipla Main Business
- 5.12.3 Cipla Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.12.4 Cipla Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.12.5 Cipla Recent Developments
- 5.13 Baxter International
- 5.13.1 Baxter International Profile
- 5.13.2 Baxter International Main Business
- 5.13.3 Baxter International Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.13.4 Baxter International Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.13.5 Baxter International Recent Developments
- 5.14 AstraZeneca
- 5.14.1 AstraZeneca Profile
- 5.14.2 AstraZeneca Main Business
- 5.14.3 AstraZeneca Subcutaneous Injectable Suspensions Products, Services and Solutions
- 5.14.4 AstraZeneca Subcutaneous Injectable Suspensions Revenue (US$ Million) & (2017-2022)
- 5.14.5 AstraZeneca Recent Developments
6 North America
- 6.1 North America Subcutaneous Injectable Suspensions Market Size by Country (2017-2028)
- 6.2 United States
- 6.3 Canada
7 Europe
- 7.1 Europe Subcutaneous Injectable Suspensions Market Size by Country (2017-2028)
- 7.2 Germany
- 7.3 France
- 7.4 U.K.
- 7.5 Italy
- 7.6 Russia
8 Asia-Pacific
- 8.1 Asia-Pacific Subcutaneous Injectable Suspensions Market Size by Region (2017-2028)
- 8.2 China
- 8.3 Japan
- 8.4 South Korea
- 8.5 India
- 8.6 Australia
- 8.7 Taiwan
- 8.8 Indonesia
9 Latin America
- 9.1 Latin America Subcutaneous Injectable Suspensions Market Size by Country (2017-2028)
- 9.2 Mexico
- 9.3 Brazil
- 9.4 Argentina
10 Middle East & Africa
- 10.1 Middle East & Africa Subcutaneous Injectable Suspensions Market Size by Country (2017-2028)
- 10.2 Turkey
- 10.3 Saudi Arabia
- 10.4 UAE
11 Subcutaneous Injectable Suspensions Market Dynamics
- 11.1 Subcutaneous Injectable Suspensions Industry Trends
- 11.2 Subcutaneous Injectable Suspensions Market Drivers
- 11.3 Subcutaneous Injectable Suspensions Market Challenges
- 11.4 Subcutaneous Injectable Suspensions Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Disclaimer
Summary:
Get latest Market Research Reports on Subcutaneous Injectable Suspensions . Industry analysis & Market Report on Subcutaneous Injectable Suspensions is a syndicated market report, published as Global Subcutaneous Injectable Suspensions Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application. It is complete Research Study and Industry Analysis of Subcutaneous Injectable Suspensions market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
